SAN FRANCISCO–(BUSINESS WIRE)–The EVERY Firm (“EVERY”), a pacesetter in crafting extremely purposeful protein substances, has been granted one more seminal patent for its recombinant Ovalbumin ingredient, increasing its protection to the European Union. EVERY’s European patent comes on the heels of the Firm’s announcement of its pioneering US patent, US 12,096,784, and additional builds on EVERY’s intensive IP property, with quite a few patents for recombinant ovalbumin in Finland, Germany, Denmark,
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/the-every-company-further-expands-its-ip-estate-with-european-union-patent-for-recombinant-ovalbumin/
